S-1/A: Actuate Therapeutics Files Amendment No. 2 for Initial Public Offering, Targeting Cancer Therapies

Actuate Therapeutics advances its IPO plans with an updated filing, focusing on developing cancer therapies through GSK-3 inhibition.

Summary

• Actuate Therapeutics, a clinical-stage biopharmaceutical company, has filed Amendment No. 2 to its Form S-1 registration statement for an initial public offering.
• The company is focused on developing therapies for difficult-to-treat cancers by inhibiting glycogen synthase kinase-3 (GSK-3).
• Their lead product candidate, elraglusib, is being evaluated in a Phase 2 trial for metastatic pancreatic cancer.
• The company is offering 5,555,556 shares of common stock with an estimated IPO price between $8.00 and $10.00 per share.
• Top-line results from the Phase 2 trial are expected in the first quarter of 2025.
• A preliminary analysis of interim data from Actuate-1801 Part 3B demonstrates a mOS of 12.2 months in the elraglusib combination therapy arm versus 7.3 months in the GnP control group arm (HR=0.60; log-rank p=0.012).
• The company intends to use the net proceeds for clinical trials, product development, research and development, clinical manufacturing, and general corporate purposes.
• The company has applied to list its common stock on the Nasdaq Capital Market under the symbol ACTU.
• The company is an emerging growth company and a smaller reporting company, allowing for certain reduced reporting requirements.

Sentiment

Score: 6

Explanation: The document presents a mix of positive and negative aspects. The positive clinical data and progress in development are encouraging, but the financial risks and dependence on a single product candidate temper the overall sentiment.

Positives

• Elraglusib has shown promising results in early clinical trials, particularly in metastatic pancreatic cancer.
• The company has secured Fast Track and Orphan Drug Designations from the FDA for elraglusib in pancreatic cancer.
• The company has a clear plan for using the IPO proceeds to advance its clinical programs.
• The company has a strong management team with extensive experience in biotechnology and healthcare investing.
• The company has a research and development collaboration with Lantern Pharma to leverage their artificial intelligence platform.

Negatives

• The company has a limited operating history and has incurred significant operating losses since its inception.
• The company's financial condition raises substantial doubt about its ability to continue as a going concern.
• The company currently depends entirely on the success of elraglusib, which is its only product candidate.
• Clinical and preclinical drug development involves a lengthy and expensive process with uncertain timelines and outcomes.
• The company may not be successful in its efforts to investigate elraglusib in additional indications.

Risks

• The company has a limited operating history and has incurred significant operating losses since its inception.
• The company's financial condition raises substantial doubt about its ability to continue as a going concern.
• The company currently depends entirely on the success of elraglusib, which is its only product candidate.
• Clinical and preclinical drug development involves a lengthy and expensive process with uncertain timelines and outcomes.
• The company may not be successful in its efforts to investigate elraglusib in additional indications.
• Use of elraglusib or any future product candidates could be associated with side effects, adverse events or other properties or safety risks.
• The termination of third-party licenses could adversely affect the company's rights to important compounds or technologies.
• The company's current elraglusib drug substance (DS) manufacturer is in China, and geopolitical relationships could affect the ability to obtain DS.
• The company relies on third parties to conduct its non-clinical studies and its clinical trials.
• If the company experiences delays or difficulties in the enrollment of subjects to its clinical trials, its receipt of necessary regulatory approvals could be delayed or otherwise adversely affected.
• If the company and its third-party licensors do not obtain and preserve protection for their respective intellectual property rights, its competitors may be able to take advantage of its development efforts to develop competing drugs.
• If the company loses key management leadership, and/or scientific personnel, and if it cannot recruit qualified employees or other significant personnel, it may experience program delays and increased compensation costs, and its business may be materially disrupted.
• The company faces significant competition from other biotechnology and pharmaceutical companies.
• Even if this offering is successful, the company will require substantial additional capital to finance its operations.
• Concentration of ownership by the company's principal stockholders limits the ability of others to influence the outcome of director elections and other transactions requiring stockholder approval.

Future Outlook

The company plans to continue clinical development of elraglusib, explore additional indications, and potentially commercialize elraglusib if approved. Future success depends on raising additional capital and achieving positive clinical trial results.

Industry Context

The announcement is relevant to the biopharmaceutical industry, specifically in the area of cancer therapeutics. It highlights the company's efforts to develop new treatments for difficult-to-treat cancers, which is a major focus in the industry. The company faces competition from other biotechnology and pharmaceutical companies developing cancer therapies.

Comparison to Industry Standards

• The mOS in patients with mPDAC is 9-11 months and the ability to extend survival by even a few months would be considered meaningful in this patient population.
• The mOS of 7.7 months in Part 1 benchmarks favorably with mOS 8-10 months for other active single agents evaluated in Phase 1.
• The elraglusib mOS of 11.9 months for the ITT compares favorably with the mOS of 11.2 months for FOLFIRINOX, the other first line regimen used for patients with mPDAC or more recently with irinotecan liposomal injection (Onivyde) (mOS=11.1 months).
• The FDA recently approved irinotecan liposomal injection (Onivyde) for the treatment of mPDAC based on the mOS=11.1 months in the NAPOLI-3 trial.

Related Party Transactions

• The Bios Equity Affiliated Funds and Kairos Ventures Affiliated Funds are parties to the Investor Rights Agreement, Voting Agreement and Right of First Refusal and Co-Sale Agreement.
• The company issued convertible promissory notes to Bios Clinical Opportunity Fund, LP, a fund affiliated with two members of the board of directors of the company and a majority shareholder.
• Mr. Richard Kenley, Vice President of Manufacturing for the Company, is an unpaid advisor for PBL and his spouse is a shareholder in PBL.

Stakeholder Impact

• Shareholders: Potential for increased value if the company successfully develops and commercializes elraglusib.
• Employees: Job security and potential for career growth.
• Patients: Access to new and potentially life-saving cancer therapies.
• Suppliers: Increased business opportunities.
• Creditors: Increased ability to repay debts if the company becomes profitable.

Next Steps

• Complete the ongoing Elraglusib Injection Phase 2 mPDAC trial (Actuate-1801 Part 3B).
• Complete the existing pediatric refractory cancer Phase 1 dose escalation trial and initiate and complete the Phase 2 portion of this study in patients with refractory Ewing sarcoma (Actuate-1902).
• Satisfy funding commitments for ongoing IIT studies for the use of Elraglusib Injection with other chemotherapy agents to treat mPDAC and a separate trial to treat recurrent salivary gland cancer.
• Finalize development plans and initiate and complete a Phase 1 dose escalation study for the Elraglusib Oral Tablet in patients with advanced, refractory solid cancer.
• Finalize development plans and initiate and enroll patients in a Phase 2 study in refractory metastatic melanoma (Actuate-2401).

Key Dates

Keywords

elraglusib, pancreatic cancer, GSK-3, clinical trials, biopharmaceutical, metastatic, oncology, FDA, therapy, cancer